Tarsus Pharmaceuticals (TARS) Depreciation & Amortization (CF) (2019 - 2026)
Tarsus Pharmaceuticals (TARS) recorded quarterly Depreciation & Amortization (CF) of $197000.0 in Q1 2026, down 20.24% quarter-over-quarter from $247000.0 in Q4 2025, and down 1.5% on a YoY basis from $200000.0 in Q1 2025.
Tarsus Pharmaceuticals (TARS) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $197000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 1.5% year-over-year to $197000.0; the TTM figure through Mar 2026 stood at $844000.0 (up 21.97% YoY), while the FY2025 annual figure was $900000.0, up 31.39% from the prior year.
- Depreciation & Amortization (CF) was $197000.0 for Q1 2026 at Tarsus Pharmaceuticals, down from $247000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $247000.0 in Q4 2023 to a low of $41000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $162588.2 across 5 years, with a median of $192000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) surged 153.66% in 2023, then tumbled 45.05% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $98000.0 in 2022, then surged by 152.04% to $247000.0 in 2023, then retreated by 22.27% to $192000.0 in 2024, then increased by 28.65% to $247000.0 in 2025, then declined by 20.24% to $197000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $197000.0 (Q1 2026), $247000.0 (Q4 2025), and $200000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Tarsus Pharmaceuticals | 2.71 Bn | 2.61 Bn | 152.66 Mn | 197,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197,000.00 |
| Mar 31, 2026 | 197,000.00 |
| Dec 31, 2025 | 247,000.00 |
| Dec 31, 2025 | 247,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 192,000.00 |
| Dec 31, 2024 | 192,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 170,000.00 |
| Mar 31, 2024 | 170,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Dec 31, 2023 | 247,000.00 |